A child with AML underwent allogeneic BMT from an HLA-identical sister donor. Prompt and stable trilineage engraftment occurred and after few months he returned to a normal life. Eight years later a primary NHL of bone developed in his sister. A partial remission was obtained by means of standard NHL treatment, but 3 months later rapid disease progression occurred with complete bone marrow invasion (ALL-L3). She was treated with a leukemia relapse protocol, obtaining a second partial remission. Unpurged bone marrow harvested from the brother, transplanted for AML 8 years earlier, was infused after conditioning with TBI and thiothepa. No GVHD prophylaxis was given. Neutrophil engraftment occurred by 14 days and platelet engraftment by 20 days after BMT. No acute GVHD was observed, but unexpectedly she developed skin and liver GVHD-like symptoms 80 days after BMT. Since the liver biopsy was suggestive of liver GVHD and in the absence of any other evidence as a possible cause of the hepatic damage, the patient started mycophenolate. Two months later serum hepatitis B markers were detectable.
probably due to a lack of regulation of the immune response by a recovering immune system, even though different factors such as drug toxicity, irradiation, and infections can mimic GVHD symptoms in the post-transplant period. 3 The only previous re-transplantation case between family members was reported in 1990 and concerned a 45-year NHL father (donor and subsequent recipient) and his AML 11-year son. 4 In our report a child with AML received a matched BMT from his sister. Eight years later, a primary NHL (Burkitt type) of bone developed in the sister. BMT with the sister's own marrow harvested from her brother was carried out.
The brother
In January 1990 a boy, aged 17 months, presented with AML (FAB M5 A) and he was treated as per protocol AIEOP LAM 87. 5 Complete remission was achieved and in June 1990, he underwent allogeneic BMT from an HLAidentical sister donor. Unpurged BM harvested from his sister was infused into him after standard conditioning with busulfan and cyclophosphamide. Cyclosporine was administered as GVHD prophylaxis. He experienced acute and chronic skin GVHD and was treated with PDN and CsA. Neutrophil engraftment occurred by 19 days and platelet engraftment by 29 days after BMT. At present, 10 years after BMT, he has no clinical or hematological evidence of acute myeloblastic leukemia or lymphoma.
The sister
In September 1998 the sister, aged 14 years, was diagnosed with primary skeletal Burkitt's NHL. 6 Total body CT scan, MRI and bone X-ray showed widespread lytic lesions involving the femurs, proximal tibiae, and pelvis bilaterally. BM biopsies were positive for Burkitt's NHL. Molecular studies showed a monoclonal Jh rearrangement (V-(D)-J). No extra-skeletal involvement was observed and her CSF was negative for malignant cells. According to Murphy's system 7 the patient was considered to have stage IV skeletal Burkitt's lymphoma and was treated as per AIEOP LNH 97 protocol (NHL BFM 95 protocol).
In February 1999, a transient partial remission was obtained with persisting bone lesions on MRI, while the BM was in first complete morphological and molecular remission.
In May 1999 the patient experienced disease progression with complete BM and peripheral blood involvement and a dramatic increase in bone disease. She was diagnosed as ALL-L3 and started a leukemia relapse protocol (AIEOP REC 98). 8 In June 1999, she attained second complete morphological and molecular BM remission and as early as September 1999 the MRI showed a marked improvement in the bone lesions. At that time she was planned to receive an 'allogeneic' BMT from her brother. Tissue typing showed A1, A2; B8, B18; Cw6; DRB 1 03 #11, identical to her brother. The mixed mono-and bi-directional lymphocyte culture was non-reactive. Cytogenetic and VNTR studies showed no differences between sister and brother.
The conditioning regimen consisted of TBI (six fractions of 200 cGY with added boosts of 200 cGY to the lower extremities and of 150 cGY to the mediastinum), and thiotepa (750 mg/m 2 for 3 days). No GVHD prophylaxis was given and on day 0 the patient received unmanipulated marrow (3.27 ϫ 10 8 nucleated cells per kg) harvested from her brother. Granulocyte engraftment occurred by day 14 and platelet engraftment by 20 days after BMT. BM examination performed on days ϩ30, ϩ100 and ϩ180 after BMT confirmed trilineage engraftment and complete morphological and molecular remission. Complete re-staging of the disease performed on day ϩ100 and ϩ180 after BMT showed stable bone lesions, not active on MRI. Unexpectedly, on day ϩ80 she developed a transient facial rash lasting a few days, started to lose her nails (both hands) and to show a progressive increase in liver function tests (GOT GPT, ALP, gGT). Hepatic ultrasonography was normal and serum viral markers were negative, while a liver biopsy showed severe siderosis, mild spotty parenchymal injury and mild portal inflammation with bile duct injury. Thus, since the bile duct injury was suggestive of liver GVHD and in the absence of any other evidence as a possible cause of the hepatic damage, the patient started mycophenolate at a dose of 1 g twice a day. Five weeks after this treatment, the ALT and AST returned to normal limits, while the ALP, ␥GT reduced markedly. One month later, liver enzymes started to rise again and serum hepatitis B markers were detected (HBsAgϩ, anti-HBsϪ, HBeAgϩ, anti-HBeϪ, anti-HBc IgMϩ, HBV-DNAϩ). She underwent lamivudine treatment (75 mg, p.o. twice a day), but became HBV-DNA and HBeAg negative only 4 and 6 months later, remaining HBsAg positive and anti-HBs negative with persistent elevation in the liver enzymes. One month after the appearance of the HBV infection (8 months post BMT) a morphological and molecular relapse occurred on BM examination and a dramatic worsening of the bone lesions was evident at MRI.
Discussion
The coincidence of two malignant disorders occurring in the same family gave us the opportunity to re-transplant a patient with her own marrow stored in vivo for 9 years.
GVHD is usually observed after allogeneic BMT and is caused by the response of donor lymphocytes to the foreign histocompatibility antigens of the recipient. A GVHD-like syndrome in syngeneic or autologous BM transplantation is still considered a rare event.
After autologous BMT, an autoimmune syndrome resembling GVHD is probably due, as with syngeneic grafts, to a failure of the regenerating immune system to acquire 'tolerance' to self-MCH antigens, leading to the development of autoreactive T cells. 9 Various twin transplant studies suggest that development of GVHD is likely to be a direct consequence of conditioning since the peripheral regulatory mechanism is suppressed by the high-dose chemotherapy given before stem cell transplantation, allowing expansion of autoreactive effector T cells during hematopoietic recovery and leading to selfreactivation following syngeneic BMT. 10, 11 Moreover, as in allogeneic BMT, viruses also seem to influence the onset of GVHD after syngeneic grafting. Several studies have shown a correlation between viral infection and GVHD-like symptoms. CMV and HSV reactivation or seroconversion of an active hepatitis B infection prior to the occurrence of GVHD-like symptoms suggests viral triggering of the disease. 3 Interestingly, in our patient GVHD symptoms antedated HBV-DNA and other marker positivity in serum by 3 months. Our hypothesis is that the virus was existing latently or replicating in the liver cells and the viral infection may have altered recipient self-antigens so that they were attacked by 'donor' lymphocytes. This hypothesis is supported by the following observations: (1) HBV-DNA by PCR was not detected in serum; (2) the donor remained negative for all HBV serum markers (HbsAg, antiHBs, antiHBc, HBV-DNA) prior and after BMT; and (3) blood products infused into the patient over the last year were all negative for HbsAg.
Furthermore, it is likely that the initial rash with hepatic dysfunction may have been due to hepatitis B infection, with negative serology secondary to the immune suppression, and that the MMF treatment temporarily suppressed the viral-induced liver damage. The MMF was actually tapered very slowly since the hepatitis could have exacerbated during withdrawal of the immunosuppressive therapy.
